Literature DB >> 9220175

Ischemic preconditioning: clinical relevance and investigative studies.

J D Schlaifer1, R A Kerensky.   

Abstract

Experimental animal studies have shown that repetitive brief coronary occlusions render the heart resistant to myocardial infarction from subsequent, more prolonged, coronary occlusions. This phenomenon in animal models has been called ischemic preconditioning. In a number of clinical scenarios, the second in a series of ischemic episodes appears to be less severe than the first, suggesting that ischemic preconditioning also occurs in humans. If the mediator of preconditioning could be identified, it is conceivable that this agent could be administered to patients with coronary artery disease as a myocardial protectant. However, the definite clinical relevance of this interesting experimental finding remains unknown. Unlike the case in animal models subjected to an abrupt occlusion, preconditioning is difficult to study in the clinical setting. This article reviews the findings and limitations of the relevant clinical studies looking for ischemic preconditioning in humans.

Entities:  

Mesh:

Year:  1997        PMID: 9220175      PMCID: PMC6656034          DOI: 10.1002/clc.4960200705

Source DB:  PubMed          Journal:  Clin Cardiol        ISSN: 0160-9289            Impact factor:   2.882


  2 in total

1.  Cardioprotection from ischemia by a brief exposure to physiological levels of ethanol: role of epsilon protein kinase C.

Authors:  C H Chen; M O Gray; D Mochly-Rosen
Journal:  Proc Natl Acad Sci U S A       Date:  1999-10-26       Impact factor: 11.205

2.  Donor treatment with a PHD-inhibitor activating HIFs prevents graft injury and prolongs survival in an allogenic kidney transplant model.

Authors:  W M Bernhardt; U Gottmann; F Doyon; B Buchholz; V Campean; J Schödel; A Reisenbuechler; S Klaus; M Arend; L Flippin; C Willam; M S Wiesener; B Yard; C Warnecke; K-U Eckardt
Journal:  Proc Natl Acad Sci U S A       Date:  2009-11-23       Impact factor: 11.205

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.